ArticleJournal of diabetes investigation2026
Elevated serum galectin-3 levels predict the incidence of type 2 diabetes mellitus in a Japanese general population: A 10-year follow-up study.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
AIMS/
introductionAlthough several studies have reported elevated serum galectin-3 levels in type 2 diabetes mellitus, its association with type 2 diabetes mellitus, in Japan, where obesity is relatively uncommon, remains unclear. We investigated whether serum galectin-3 levels can be a predictive marker for type 2 diabetes mellitus in a Japanese general population. MATERIALS AND
methodsA total of 433 participants who underwent a health check-up in Nagasaki between 2013 and 2014 were enrolled; of these, 307 participants completed follow-up by 2023. Participants were classified into quartiles based on serum galectin-3 levels measured by a sandwich enzyme immunoassay, and multivariate logistic regression analysis was performed.
resultsThe serum galectin-3 levels were associated with type 2 diabetes mellitus prevalence (P = 0.002) in the regression analysis. Over the 10-year follow-up, the highest galectin-3 quartile had a higher type 2 diabetes mellitus incidence than the lowest galectin-3 quartile (adjusted odds ratio: 5.75; 95% confidence interval: 1.08-30.65). Subgroup analysis stratified by body mass index revealed that each 1-standard deviation increase in serum galectin-3 level was associated with a significantly increased risk of incident type 2 diabetes mellitus in the low body mass index group, but not in the high body mass index group.
conclusionsThe serum galectin-3 levels were significantly associated with type 2 diabetes mellitus prevalence and incidence in a general Japanese population, particularly among individuals without obesity. Galectin-3 may be a useful biomarker for identifying individuals at risk of type 2 diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.